Lilly's Foundayo Grabs 30%+ of New US Oral Obesity Patients, Closing Gap on Novo
LLY sits 60% above its 52-week low of $712.05.
Summary
Lilly disclosed that Foundayo, its oral obesity drug, has captured over 30% of new US patients in the oral weight-loss market, a significant gain from Novo Nordisk's earlier 90% share estimate in August. This indicates rapid adoption and competitive momentum in a market expected to exceed $100B annually in the US by 2030. The news also highlights Zepbound's strong uptake in the Medicare pilot, with 60-70% of enrollees being new to treatment. Investors are closely watching oral GLP-1 dynamics as they could expand the addressable market beyond injection-averse patients. The disclosure comes ahead of potential regulatory submissions for retatrutide, Lilly's next-gen obesity drug, and follows a strong Q2 with 48% revenue growth.
At the time of this announcement, LLY was trading at $1,138.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.